It was early October 2019 and Uğur Şahin was standing in a Kansas City, Mo., parking lot, sweating under the blazing midafternoon sun. He and a few colleagues had spent weeks crisscrossing the U.S. and visiting different cities in Europe. They were trying to drum up investor interest in the initial public offering of BioNTech SE, the German biotechnology company Dr. Şahin had started. The trip wasn’t going well.
Read more here.
